"rationale","instanceType","versionIdentifier","id","uuid:ID"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion","2","StudyVersion_1","336007a6-7600-416c-a05e-4b33289cdb71"
